Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2012. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the company's issued share capital as of May 31, 2012:
- Total Issued Shares: 5,464,863,186 Ordinary Shares of 25p each.
- Treasury Shares: 446,932,927 Ordinary Shares held in Treasury.
- Total Voting Rights: 5,017,930,259.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,017,930,259) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (446,932,927) when calculating diluted ownership percentages.
- Note that this filing does not contain financial performance metrics; refer to Form 20-F or quarterly earnings releases for revenue and profit data.